Payment overview · 2025
General Payments
$204.66
13 reported records · 6 companies
Healthcare provider profile · identity verified
Russell D. Ingram, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BETHANY, OK · NPI 1043475353
Verified facts
What the public records show
CMS Open Payments records show Russell D. Ingram, M.D. received $204.66 in general payments during 2025 across 13 reported records.
Abbott Laboratories accounted for 29.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $61.10 | 29.9% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $48.60 | 23.8% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $33.68 | 16.5% | 2 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $26.74 | 13.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.89 | 8.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.65 | 8.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $204.66 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $61.10 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $33.72 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $33.72 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $33.68 | 2 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $26.74 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.89 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.89 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 97 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
97 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
86 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
22 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 356 | 94 |
| Atorvastatin Calcium | Atorvastatin Calcium | 285 | 85 |
| Amlodipine Besylate | Amlodipine Besylate | 268 | 65 |
| Gabapentin | Gabapentin | 250 | 60 |
| Losartan Potassium | Losartan Potassium | 238 | 69 |
| Lisinopril | Lisinopril | 233 | 59 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 232 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 203 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 178 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 167 | 51 |
| Omeprazole | Omeprazole | 162 | 49 |
| Prednisone | Prednisone | 161 | 118 |
| Furosemide | Furosemide | 158 | 45 |
| Metformin Hcl | Metformin Hcl | 155 | 39 |
| Metformin Hcl Er | Metformin Hcl | 152 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 149 | 39 |
| Simvastatin | Simvastatin | 148 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 124 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 121 | 37 |
| Trazodone Hcl | Trazodone Hcl | 111 | 38 |
| Sertraline Hcl | Sertraline Hcl | 108 | 32 |
| Celecoxib | Celecoxib | 105 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 105 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 104 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 100 | 25 |
| Mounjaro | Tirzepatide | 99 | 16 |
| Famotidine | Famotidine | 97 | 28 |
| Ozempic | Semaglutide | 97 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 96 | 22 |
| Potassium Chloride | Potassium Chloride | 94 | 31 |
| Azithromycin | Azithromycin | 92 | 70 |
| Pregabalin | Pregabalin | 91 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 90 | 38 |
| Montelukast Sodium | Montelukast Sodium | 89 | 21 |
| Eliquis | Apixaban | 86 | 22 |
| Meloxicam | Meloxicam | 85 | 28 |
| Carvedilol | Carvedilol | 81 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 80 | 20 |
| Allopurinol | Allopurinol | 76 | 21 |
| Glimepiride | Glimepiride | 68 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 67 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 65 | 20 |
| Tramadol Hcl | Tramadol Hcl | 62 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 59 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 57 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | 15 |
| Alprazolam | Alprazolam | 54 | 13 |
| Baclofen | Baclofen | 50 | 30 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 49 | 12 |
| Buspirone Hcl | Buspirone Hcl | 46 | suppressed |
| Valsartan | Valsartan | 46 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 44 | suppressed |
| Cephalexin | Cephalexin | 43 | 33 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 42 | 35 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 22 |
| Alendronate Sodium | Alendronate Sodium | 41 | 15 |
| Estradiol | Estradiol | 41 | 15 |
| Cefdinir | Cefdinir | 39 | 34 |
| Donepezil Hcl | Donepezil Hcl | 38 | suppressed |
| Nystatin | Nystatin | 38 | 17 |
| Finasteride | Finasteride | 37 | 14 |
| Ibuprofen | Ibuprofen | 36 | 12 |
| Jardiance | Empagliflozin | 36 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | 11 |
| Ondansetron Odt | Ondansetron | 34 | 11 |
| Valacyclovir | Valacyclovir Hcl | 34 | 16 |
| Ezetimibe | Ezetimibe | 32 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 27 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 29 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 27 |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 17 |
| Anastrozole | Anastrozole | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 13 |
| Fluconazole | Fluconazole | 26 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 23 |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Clonidine | Clonidine | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 12 |
| Methenamine Hippurate | Methenamine Hippurate | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 13 |
| Trulicity | Dulaglutide | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | 11 |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $204.66 · 13 records | Abbott Laboratories | ABRYSVO, AIRSUPRA, COMIRNATY, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, NEXPLANON, NURTEC ODT, Ozempic, PREVNAR 20, Rybelsus, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error